This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
Chaga contains one of the highest ORAC (oxygen radical absorbance capacity) values of any food, primarily due to its melanin content, betulinic acid, and superoxide dismutase (SOD). These compounds neutralize free radicals and reduce oxidative stress at the cellular level. Additionally, chaga's beta-glucans and polysaccharides modulate immune function by activating macrophages and natural killer cells. This dual mechanism—antioxidant protection plus immune modulation—underlies chaga's traditional use as a wellness tonic (Evidence Level B).
Can chaga interact with medications?
Yes, chaga has several clinically relevant drug interactions. Due to its blood sugar-lowering effects, chaga can potentiate diabetes medications like metformin or insulin, increasing hypoglycemia risk. Chaga may also enhance anticoagulant effects of blood thinners such as warfarin, raising bleeding risk. Because chaga stimulates immune activity, it may interfere with immunosuppressive medications. Patients on these medications should consult a healthcare provider before using chaga supplements (Evidence Level C).
How much chaga should I take daily?
The typical adult dosage for chaga is 1-3 grams of extract daily, or 1-3 cups of chaga tea. For powdered extracts, follow manufacturer instructions as concentrations vary. Start with lower doses to assess tolerance, as chaga can cause gastrointestinal upset in sensitive individuals. Chaga is best consumed consistently over time for cumulative benefits. No standardized clinical dosing has been established; recommendations are based on traditional use and expert consensus (Evidence Level D - Traditional).
Is chaga safe during pregnancy and breastfeeding?
Chaga is considered unsafe during pregnancy and breastfeeding. There is insufficient safety data for use in pregnant or nursing women, and chaga's immune-stimulating properties pose theoretical risks to fetal development. Additionally, chaga contains high oxalate levels, which may stress kidneys during pregnancy. Women who are pregnant, trying to conceive, or breastfeeding should avoid chaga supplements entirely (Evidence Level D - Traditional contraindication).
What is chaga mushroom good for?
Chaga has been used traditionally as an immune tonic, digestive aid, and general wellness supplement. Modern research suggests potential anti-inflammatory and antioxidant benefits due to its exceptionally high ORAC value. Preliminary laboratory studies indicate possible anticancer properties attributed to betulinic acid, though human clinical trials are lacking. Chaga is commonly used to support immune function and reduce oxidative stress, but more rigorous human research is needed (Evidence Level B).
Can chaga cause kidney stones?
Yes, chaga contains significant oxalate content and may increase kidney stone risk with excessive or long-term use. Individuals with a history of calcium oxalate kidney stones or existing kidney disease should avoid chaga or use it only under medical supervision. Moderate intake within recommended dosages (1-3g daily) is unlikely to cause problems in healthy individuals with normal kidney function. Staying well-hydrated when consuming chaga may help reduce stone formation risk (Evidence Level C).
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Inonotus obliquus, known as Chaga, is a medicinal mushroom used since the sixteenth century for various therapeutic purposes [PMID:38813471]. Modern research indicates it possesses antioxidant, anti-inflammatory, anticancer, and anti-diabetic properties [PMID:38813471, PMID:38116085, PMID:39170453].
Background
Chaga (Inonotus obliquus) is a parasitic fungus that grows on birch trees [PMID:29484963]. It is characterized as a medicinal mushroom and functional food with high nutritional value [PMID:37513265, PMID:19407959].
Traditional uses
Traditional applications include the treatment of gastrointestinal cancer, diabetes, bacterial infections, liver diseases [PMID:38813471], breast, cervix, and skin cancers [PMID:38116085], gastritis, gastric ulcers, and tuberculosis of the bones [PMID:23149251, PMID:32877719]. It has also been used in pipe smoking rituals and mystical future forecasts [PMID:38116085].
Active compounds
Bioactive compounds include polysaccharides (specifically Inonotus obliquus polysaccharide or IOPS) [PMID:33947037], triterpenoids (such as inotodiol, betulin, lanosterol, ergosterol, and $\beta$-sitosterol) [PMID:35335249, PMID:40243601], polyphenols, flavonoids, steroids, and lignin metabolites [PMID:38813471, PMID:38116085, PMID:39202879].
Mechanism of action
Mechanisms include the suppression of iNOS and NO production via lanostanoids [PMID:33434790], regulation of the NOS-cGMP-PDE5 signaling pathway for glucolipid metabolism [PMID:39059831], and induction of autophagy via the AMPK-mTOR pathway in breast cancer cells [PMID:33798660]. It may also act by inhibiting energy metabolism (glycolysis and mitochondrial respiration) and suppressing STAT3 activity in oral cancer cells [PMID:38720012], and regulating Nrf2 signaling to exert antioxidative effects [PMID:30878614].
Clinical evidence
Evidence DBladder Cancer (Dog Organoids)
Chaga extract inhibited cell viability in a concentration-dependent manner, arrested the cell cycle, and induced apoptosis [PMID:37153767].
Evidence DBreast Cancer (Mice/In Vitro)
Oral administration of Chaga mushroom extract (2 g/kg) demonstrated anti-tumor effects in 4T1 tumor-bearing BALB/c mice [PMID:33798660].
Evidence DOral Cancer (In Vitro)
Extract reduced cell viability and proliferation of HSC-4 cells by inhibiting glycolysis and mitochondrial membrane potential [PMID:38720012].
Evidence DRenal Fibrosis (Mice)
Chaga ameliorates folic acid-induced renal fibrosis in mice [PMID:40160460].
Evidence DType 2 Diabetes (Rats)
Chaga extracts (50 and 100 mg/kg) were used to treat glucolipid metabolism disorders and abnormal renal functions in HFD/STZ-induced T2DM rats [PMID:39059831].
Evidence DAtopic Dermatitis (Mice)
Safety & adverse effects
A case report identified oxalate nephropathy (diffuse tubular atrophy and interstitial fibrosis) in a patient ingesting 4-5 teaspoons of Chaga mushroom powder daily, noting that Chaga contains extremely high oxalate concentrations [PMID:23149251]. Additionally, wild chaga conks have been found to contain high activity concentrations of 40K and mild contamination with 137Cs [PMID:37089251].
Evidence summary
The current evidence is primarily based on in vitro studies, animal models (mice/rats), and a single case report. There is a lack of human clinical trials (RCTs) or systematic reviews of clinical data, placing the overall strength of clinical evidence at level D.
PubMed sources
1.PMID: 38813471 (2024) — Therapeutic properties of Inonotus obliquus (Chaga mushroom): A review. · Mycology
2.PMID: 38116085 (2023) — Chaga mushroom: a super-fungus with countless facets and untapped potential. · Frontiers in pharmacology
3.PMID: 37513265 (2023) — Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review. · Molecules (Basel, Switzerland)
4.PMID: 35335249 (2022) — Supercritical CO2 Extraction of Triterpenoids from Chaga Sterile Conk of Inonotus obliquus. · Molecules (Basel, Switzerland)
5.PMID: 37153767 (2023) — Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder cancer organoids. · Frontiers in pharmacology
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
7.PMID: 40160460 (2025) — Inonotus obliquus (chaga) ameliorates folic acid-induced renal fibrosis in mice: the crosstalk analysis among PT cells, macrophages and T cells based on single-cell sequencing. · Frontiers in pharmacology
8.PMID: 39170453 (2024) — A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms. · Heliyon
12.PMID: 34195023 (2021) — Inonotus obliquus - from folk medicine to clinical use. · Journal of traditional and complementary medicine
13.PMID: 33639077 (2021) — Medicinal Mushrooms against Influenza Viruses. · International journal of medicinal mushrooms
14.PMID: 33800424 (2021) — Comparison of Polysaccharides Extracted from Cultivated Mycelium of Inonotus obliquus with Polysaccharide Fractions Obtained from Sterile Conk (Chaga) and Birch Heart Rot. · Journal of fungi (Basel, Switzerland)
15.PMID: 39059831 (2024) — Inonotus obliquus (Chaga) against HFD/STZ-induced glucolipid metabolism disorders and abnormal renal functions by regulating NOS-cGMP-PDE5 signaling pathway. · Chinese journal of natural medicines
16.PMID: 40868987 (2025) — Molecular Mechanisms of Phytochemicals from Chaga Mushroom (Inonotus obliquus) Against Colorectal Cancer: Insights from Network Pharmacology, Molecular Docking, and Bioinformatics. · International journal of molecular sciences
17.PMID: 19407959 (2009) — Progress of research on Inonotus obliquus. · Chinese journal of integrative medicine
19.PMID: 39202879 (2024) — Impact of Incorporating Dried Chaga Mushroom (Inonotus obliquus) into Gluten-Free Bread on Its Antioxidant and Sensory Characteristics. · Molecules (Basel, Switzerland)
20.PMID: 38720012 (2024) — Chaga mushroom extract suppresses oral cancer cell growth via inhibition of energy metabolism. · Scientific reports
22.PMID: 38046279 (2023) — Chaga mushroom triterpenoids as adjuncts to minimally invasive cancer therapies: A review. · Current research in toxicology
23.PMID: 32877719 (2021) — Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus. · Journal of ethnopharmacology
24.PMID: 40508014 (2025) — Elucidating the Anti-Diabetic Mechanisms of Mushroom Chaga (Inonotus obliquus) by Integrating LC-MS, Network Pharmacology, Molecular Docking, and Bioinformatics. · International journal of molecular sciences
25.PMID: 33798660 (2021) — Chaga mushroom extract induces autophagy via the AMPK-mTOR signaling pathway in breast cancer cells. · Journal of ethnopharmacology
26.PMID: 40243601 (2025) — Comparative Study of Chaga (Inonotus obliquus) Dietary Supplements Using Complementary Analytical Techniques. · International journal of molecular sciences
27.PMID: 41581894 (2026) — Chaga Mushroom (Inonotus obliquus) Attenuates DNCB-Induced Atopic Dermatitis by Modulating Oxidative Stress and Cytokine Expression. · Journal of microbiology and biotechnology
28.PMID: 30878614 (2019) — Inonotus obliquus polysaccharides protect against Alzheimer's disease by regulating Nrf2 signaling and exerting antioxidative and antiapoptotic effects. · International journal of biological macromolecules
29.PMID: 27562990 (2016) — [Composition and biological activity of triterpenes and steroids from Inonotus obliquus (chaga)]. · Biomeditsinskaia khimiia
30.PMID: 29484963 (2018) — Chaga ( Inonotus obliquus), a Future Potential Medicinal Fungus in Oncology? A Chemical Study and a Comparison of the Cytotoxicity Against Human Lung Adenocarcinoma Cells (A549) and Human Bronchial Epithelial Cells (BEAS-2B). · Integrative cancer therapies